The first week of simulation was a negative for the industry leaders, and four of the five big ticket stocks we selected to hold onto for the simulation lost money in their first week. As the week went on, the stocks recovered. The second week of trading was vastly more beneficial to the long-term account, and four of the five stocks gained value. The end of the week totals, in descending order of profit; Pfizer, with $572.88 gained overall, Merck with $405.17 gained, Johnson and Johnson with $292.31 in gains, and finally, Baxter with a gain of $237.87. Eli Lilly was losing well over a $1,000 off its cost basis mid-week, its stock finally ended a multi-week tumble and recovered late week to achieve losses of only $303.84 overall.